RANKL Antibody (G-1): sc-377079

RANKL Antibody (G-1) is a mouse monoclonal IgG1 kappa kappa light chain antibody raised against amino acids 46-317, representing full-length RANKL of human origin, effectively detecting RANKL proteins of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). RANKL, also known as Receptor Activator of Nuclear Factor Kappa-B Ligand, TNFSF11, CD254, TRANCE, OPGL, or ODF, is a type II transmembrane protein crucial for bone remodeling and immune system regulation. Post-translational modifications of RANKL, such as glycosylation, are important for stability, activity, and interaction with RANK receptor. Glycosylation enhances RANKL′s ability to bind to RANK, activating signaling pathways like NF-κB and JNK, which are essential for osteoclast differentiation and activation. The structural integrity and post-translational modifications of RANKL are vital for function in regulating T cells and osteoclasts, impacting processes like bone resorption and immune responses. Alterations in RANKL expression or modifications can contribute to pathological conditions such as osteoporosis, rheumatoid arthritis, and bone metastasis. RANKL monoclonal antibody (G-1) offers high specificity and sensitivity for detecting RANKL, available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. Anti-RANKL antibody (G-1) serves as an essential tool for researchers studying the role of RANKL in bone metabolism and immune regulation, aiding in the development of therapeutic interventions for related diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

RANKL Antibody (G-1) References:

1. [Osteoporosis and RANKL signal].  |  Nakamura, M. and Udagawa, N. 2011. Clin Calcium. 21: 1149-55. PMID: 21814019
2. RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases.  |  Yasuda, H. 2013. World J Orthop. 4: 207-17. PMID: 24147256
3. Effects of RANKL-Targeted Therapy in Immunity and Cancer.  |  Cheng, ML. and Fong, L. 2014. Front Oncol. 3: 329. PMID: 24432249
4. Regulatory mechanisms of RANKL presentation to osteoclast precursors.  |  Honma, M., et al. 2014. Curr Osteoporos Rep. 12: 115-20. PMID: 24477414
5. Role of the RANK/RANKL pathway in breast cancer.  |  Kiesel, L. and Kohl, A. 2016. Maturitas. 86: 10-6. PMID: 26921922
6. RANKL-independent osteoclastogenesis in the SH3BP2 cherubism mice.  |  Kittaka, M., et al. 2020. Bone Rep. 12: 100258. PMID: 32258251
7. Local RANKL delivery improves socket healing in bisphosphonate treated rats.  |  Soundia, A., et al. 2021. Bone. 148: 115945. PMID: 33836308
8. RANKL inhibition halts lesion progression and promotes bone remineralization in mice with fibrous dysplasia.  |  Liu, Z., et al. 2022. Bone. 156: 116301. PMID: 34952228
9. [Discovery of RANKL and the current and future impact of its research].  |  Yasuda, H. 2023. Nihon Yakurigaku Zasshi. 158: 247-252. PMID: 37121707
10. RANKL signaling drives skeletal muscle into the oxidative profile.  |  Cavalcanti de Araújo, PH., et al. 2024. J Bone Miner Res. 39: 753-764. PMID: 38619281

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-RANKL Antibody (G-1) has 44 citations in a variety of scientific publications.

Primary antibodies like Anti-RANKL Antibody (G-1) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

RANKL Antibody (G-1) Specifications

Alternate Product Name: TNFSF11

Product Clone Name: G-1

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 46-317

Epitope Target: RANKL

Epitope Species: human

Product Reactivity/Detection: RANKL

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 44 citations in various scientific publications

Available Conjugates/Forms for RANKL Antibody (G-1): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin

The preferred RANKL antibody is RANKL Antibody (12A668): sc-52950.